Medpage Today on MSN

Adalimumab Bests Conventional Therapy For Steroid Sparing in Uveitis

ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the ...
Monthly Prescribing Reference

Adalimumab-adbm Injection, an Interchangeable Biosimilar to Humira, Now Available

Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...
Nasdaq

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

PARSIPPANY, N.J. & REYKJAVÍK, Iceland--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today ...
Nasdaq

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical ...
Healio

Boehringer Ingelheim, Quallent partner to expand Humira biosimilar access

Please provide your email address to receive an email when new articles are posted on . Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm. The existing biosimilar ...
The Manila Times

FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...
Drug Store News

Mark Cuban Cost Plus Drug Company partners with Coherus to offer Humira biosimilar

Mark Cuban Cost Plus Drug Company and Coherus BioSciences are planning to offer customers Yusimry (adalimumab-aqvh), a biosimilar of AbbVie's Humira (adalimumab injection), in July 2023. The ...
Seeking Alpha

Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023

REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023* with a list price of ...
Healio

Etanercept, adalimumab improve wellbeing in non-systemic juvenile idiopathic arthritis

Please provide your email address to receive an email when new articles are posted on . Etanercept and adalimumab are both impactful at improving the health of ...